Results: Patients with high serum ROM level showed poorer recurrence-free survival and overall survival than patients with low serum ROM level (log rank test; P = 0.2913 and P = 0.1016). DNA methylation profiling revealed that serum ROM revel was significantly associated with aberrant SIM-1 methylation (P = 0.0355). The average levels of serum ROM were 306. AE 4.7 in patients with methylated SIM-1 (n = 17) and 348 AE 3.9 in patients without SIM-1 methylation (n = 33) (P = 0.0071).
is required, the results of this study indicate that inducing epigenetic gene silencing through DNA methylation in specific genes may be one of the underlying mechanisms by which reactive oxygen species are implicated in various features of malignant tumours. Background and Aims: The development of cancer immunotherapy in recent years has been remarkable, and many studies have been published on clinical effects of immune checkpoint inhibitors. These drugs are also effective in advanced or recurrent non-small cell lung cancer (NSCLC) resistant to cytotoxic anticancer drugs or molecular-targeted drugs and are excellent treatment options that can prolong overall survival of patients. However, to date, few studies have specifically examined treatment outcomes of immune checkpoint inhibitors in recurrent NSCLC.
Methods:
We retrospectively reviewed 18 cases with postoperative recurrent NSCLC treated with immune checkpoint inhibitors in our hospital.
Results: The 18 cases comprised 14 males and 4 females with a median age of 71 years [range, 65-75 years] . The histological type of cancer was squamous cell carcinoma in 7 cases and adenocarcinoma in 11. Those with adenocarcinoma included 1 EGFR-mutation-positive case and 1 case with ROS1 translocation. The treatment drug used was pembrolizumab in 1 case and nivolumab in 1 case. The treatment was administered as first-line therapy in 1 case, second-line therapy in 10 cases, third-line or later therapy in 7 cases. Best overall response was CR in 2 cases, PR in 4 cases, SD in 8 cases, and unevaluable in 1 case, with a response rate of 33% and a disease control rate of 50%. Adverse events were interstitial pneumonia in 2 cases, colitis in 1 case, sarcoidosis in 1 case, skin rash in 1 case, and eosinophilic fasciitis in 1 case.
Conclusion:
Although the sample size in this study was small, the response rate and the disease control rate were 30% and 50%, respectively, which were superior to those reported by past studies. We intend to further investigate in a larger sample size the treatment effects and safety of immune checkpoint inhibitors in actual clinical settings along with a statistical analysis. SNPs in 71 genes in the TNF/TNFR signalling pathway and extracted genotyping data from the PLCO genome-wide association study (GWAS) dataset. We performed Cox proportional hazards regression analysis to evaluate associations between the identified SNPs and survival and validated the significant SNPs, which were further analyzed for their functional relevance
Results: Thirty-three SNPs in the PLCO dataset were found to be statistically significant in the single-locus analysis, of which rs4978754 IKBKAP CT+TT and TNFRSF1B rs677844 TC+CC genotypes of two validated SNPs (rs4978754 C>T and rs677844 T>C, respectively) predicted a better overall survival (OS) (P = 0.004 and 0.002, respectively). The number of their combined genotypes predicted a better OS in a genotype dose-response manner (P < 0.001) in a multivariable Cox model. The meta-analysis of these two validated SNPs showed a favourable overall survival associated with the rs677844 C and rs4978754 T alleles (P < 0.05). These two validated SNPs were predicted by the RegulomeDB score to be potentially functional. IKBKAP mRNA expression levels were significantly higher in lung cancer tissues than in normal tissues (P < 0.001), while TNFRSF1B mRNA expression levels were significantly lower in lung cancer tissues than in normal tissues (P < 0.001).
In a pathway-based analysis of genetic variants in PLCO and Harvard GWAS datasets, we identified TNFRSF1B rs677844 T>C and IKBKAP rs4978754 C>T to be associated with survival in NSCLC patients. 
